Exscientia vs Regard AI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Exscientia employs 100-500 people, while Regard AI has 50-200 employees.

Exscientia has raised more in total funding at $500M, compared to Regard AI's $30M — a gap of $470M.

Exscientia holds the higher Awaira Score at 72/100, compared to Regard AI's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 17-point gap that reflects meaningful differences in scale or traction.

Exscientia was founded by Andrew Hopkins in 2012. Regard AI's founder information is not currently available in our database.

Exscientia: Exscientia is an AI-driven drug design company that uses automated design-make-test-analyse cycles to generate drug candidates with the goal of reducing the time and cost of small molecule drug discovery. The Oxford-originated company builds generative chemistry models and automated laboratory robotics that together create a closed-loop system for molecular design, synthesis, and assay testing, producing candidates in months rather than the years required by conventional medicinal chemistry programmes.\n\nThe company went public on NASDAQ under the ticker EXAI, having raised over $500 million in combined public and private funding from investors including Bristol-Myers Squibb, Celgene, SoftBank, and GT Healthcare Capital Partners. Exscientia has clinical-stage programmes in oncology and neuropsychiatry and reports being the first company to advance AI-designed drug candidates into human clinical trials. The company has multiple pharma partnerships including agreements with Bristol-Myers Squibb, Sanofi, and Evotec that provide milestone and royalty revenue.\n\nExscientia competes in the AI drug design space against Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics, and Insilico Medicine. The company differentiates through its integrated automated laboratory approach, which combines computational design with physical synthesis and testing in a single workflow rather than treating AI design as a separate step before conventional chemistry. Its public market position and disclosed clinical programmes provide transparency benchmarks against which the broader AI drug discovery sector is measured by investors and pharmaceutical partners. Regard AI: Regard AI builds an AI clinical documentation assistant that integrates with hospital electronic health record systems to automatically identify potential diagnoses, surface relevant clinical evidence from patient records, and generate structured documentation for physician review. The system is designed to reduce the documentation burden on hospitalists and clinical teams while improving diagnostic completeness and coding accuracy.\n\nThe company raised approximately 30 million USD and has deployed across hospital systems focused on reducing physician administrative load, a problem that contributes to clinician burnout and documentation errors with downstream billing and quality implications. Regard operates as a background analysis layer that surfaces findings without requiring clinicians to change their existing EHR workflow.\n\nClinical documentation AI sits at the intersection of physician workflow optimization and revenue cycle management, giving it a dual value proposition that justifies enterprise procurement from both clinical operations and hospital finance departments. Regard competes with Nuance DAX, Abridge, and other ambient documentation tools, but its focus on diagnostic suggestion and coding completeness rather than pure transcription differentiates its clinical and financial value story.

Exscientia was founded first in 2012, giving it 5 years of additional market experience. Regard AI was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Exscientia has approximately 100-500 employees, while Regard AI has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Exscientia and Regard AI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.